news
Lilly to end contract with UCSD for A4 Alzheimer’s study
5 August 2015 | By Victoria White
Lilly has notified UCSD of its intent to end its contract with the University for the management of the Alzheimer's disease A4 study...
List view / Grid view
Alzheimer's
news
Florbetapir scans help with patient diagnosis and management
23 July 2015 | By Victoria White
New data shows that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management of patients...
news
Aducanumab demonstrates promising Phase 1b results in Alzheimer’s disease
22 July 2015 | By Victoria White
Biogen has announced new results from an interim analysis of the Phase 1b PRIME study of aducanumab in patients with prodromal or mild Alzheimer’s disease...
news
Data suggests Lilly’s solanezumab slows progression of mild Alzheimer’s
22 July 2015 | By Victoria White
Lilly has announced results suggesting that solanezumab slows the progression of Alzheimer's in patients with mild disease...
news
AXON Neuroscience’s vaccine designed to halt Alzheimer’s finishes Phase 1 clinical trial
8 July 2015 | By Victoria White
AXON Neuronscience's vaccine intended to be a disease modifying drug for Alzheimer’s disease patients has passed a Phase 1 safety trial...
news
Patients with dementia not getting enough help from health and social care services, say GPs
6 July 2015 | By Victoria White
Over three quarters of UK GPs think their patients with dementia rely on family as they do not get enough help from health and social care services...
news
Sembragiline fails to meet primary endpoint in Phase IIb trial in Alzheimer’s disease
2 July 2015 | By Victoria White
Evotec and Roche have provided an update on the initial results of the Phase IIb trial with Sembragiline for the treatment of Alzheimer's disease...
news
Phase 2/3 study of ELND005 did not meet primary efficacy endpoint
24 June 2015 | By Victoria White
A Phase 2/3 clinical study of ELND005 in agitation and aggression in patients with Alzheimer's disease (AD) did not meet its primary efficacy endpoint...
news
Heptares announces positive outcome of Phase 1a study of HTL9936
17 June 2015 | By Victoria White
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, has announced the positive outcome of its Phase 1a study with HTL9936...
news
Alzheimer’s disease treatment market value will exceed $13 billion by 2023, says GlobalData
7 May 2015 | By Victoria White
The global market for Alzheimer’s disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023...
news
New guide launched by experts to help carers identify pain in people with dementia
23 April 2015 | By Victoria White
Napp and a group of experts in the fields of pain management and dementia care have launched a training resource to help carers identify signs of pain...
news
EU Disease Lens brings visibility and insight into the most critical diseases
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
news
Biogen Idec presents positive interim results from Phase 1b study of investigational Alzheimer’s Disease treatment aducanumab
23 March 2015 | By Victoria White
Biogen Idec has announced data from the Phase 1b study of aducanumab, in which the drug demonstrated positive results in patients with prodromal or mild AD...
news
Alzheimer’s Disease Treatment pipeline remains large despite 95% attrition rate, says GBI Research
24 February 2015 | By GBI Research
While drug candidates for Alzheimer’s Disease fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research...
news
Actinogen Ltd acquires Edinburgh BioQuarter spin-out to develop treatment for Alzheimer’s dementia
31 October 2014 | By Actinogen Ltd
Actinogen Ltd, an Australian biotechnology company, has acquired Edinburgh BioQuarter spin-out, Corticrine Ltd in a deal facilitated and introduced by Professor Alan Boyd of Boyds...
